Trade Mark Journal No.2025/026 27 June 2025
WO0000001859357 (5,44)
Office of origin: United States of America
Date of International Registration:17 April 2025
Date of designation in the UK:
17 April 2025
International priority date claimed: 24 October 2024
(United States of America)
(98818944)
- Class 5
- Antimicrobial preparations for inhibiting bacteria; drug delivery agents in the form of coated capsules that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention of autoimmune, inflammatory, bacterial, and antibiotic-induced infectious conditions; pharmaceutical preparations for delivery of oxygen to tissue; therapeutic agents for delivery of oxygen to human tissue.
- Class 44
- Medical diagnostic services; medical services in the field of antibiotic-induced infection and gastroenterology; providing information in the fields of health and wellness in the field of autoimmune conditions, inflammatory conditions, bacterial conditions, antibiotic-induced infectious conditions, and oxygen therapy via a website; providing medical information in the field of autoimmune conditions, inflammatory conditions, bacterial conditions, antibiotic-induced infectious conditions, and oxygen therapy.
LPOXY THERAPEUTICS, INC.
Representative: Knobbe, Martens, Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine CA 92614, UNITED STATES OF AMERICA